Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
A new editorial was published in Oncotarget's Volume 15 on October 1, 2024, entitled, “Transplant or no transplant for TP53 mutated AML.”
As highlighted in this editorial, TP53 mutations (mut) occur in 10–15% of acute myeloid leukaemia (AML) cases, commonly associated with therapy-related AML (t-AML) and complex cytogenetics (CG).
TP53-mut AML is inherently resistant to conventional chemotherapies and continues to show a poor prognosis, even with venetoclax-based therapies.
Allogeneic haematopoietic stem cell transplant (allo-HCT) remains a potential curative option, though only 10–15% of patients receive it.
In a recent study, allo-HCT was the only variable significantly improving survival, despite only 16% of patients successfully bridging to it.
In their editorial, researchers Talha Badar, Moazzam Shahzad, Ehab Atallah, Mark R.
Litzow, and Mohamed A.Kharfan-Dabaja from the Division of Haematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Programme at Mayo Clinic (Jacksonville, Florida) evaluated the outcomes of TP53-mutated AML patients based on data from the Consortium of Myeloid Malignancies and Neoplastic Diseases (COMMAND).
The study found a “dismal” survival rate of 8.5 months, with no significant difference among treatment types, and allo-HCT was the only variable associated with improved survival.
The authors also report on the “better long-term outcomes” when allo-HCT was performed during Complete Remission 1 (CR1) in previous observations.
They acknowledge the limitations of their retrospective analysis, including selection bias, data heterogeneity from participating institutions, and the lack of complete molecular data prior to allo-HCT that might have influenced the results.
Nevertheless, the findings are encouraging and suggest that allo-HCT improves long-term outcomes in this poor prognostic disease, where effective therapies remain limited.
“In summary, this study reported improved survival when allo-HTC was performed in CR1 versus after later lines of therapy.”
Source: Impact Journals LLC
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.